Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults

International Journal of Cancer

Volumn 131, Issue 1, 2012, Pages 193-200

  Borena, Wegene ^a   Strohmaier, Susanne ^a   Lukanova, Annekatrin ^b   Bjørge, Tone ^c,d   Lindkvist, Björn ^e   Hallmans, Goran ^f   Edlinger, Michael ^a   Stocks, Tanja ^f   Nagel, Gabriele ^g   Manjer, Jonas ^h   Engeland, Anders ^c,d   Selmer, Randi ^c   Häggström, Christel ^f   Tretli, Steinar ⁱ   Concin, Hans ^j   Jonsson, Hãkan ^f   Stattin, Pär ^f   Ulmer, Hanno ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF BERGEN   (Norway)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g UNIVERSITY OF ULM   (Germany)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ CANCER REGISTRY OF NORWAY   (Norway)

^j AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

more..

Author keywords

cohort study; epidemiology; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; metabolic syndrome

Indexed keywords

CHOLESTEROL; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; AUSTRIA; BIRTH YEAR; BLOOD PRESSURE; BODY MASS; CANCER RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NORWAY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING HABIT; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AUSTRIA; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPIDS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NORWAY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; TRIGLYCERIDES;

EID: 84860215803     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26338     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Kamangar F, Dores GM, Anderson WF,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
3. El-Serag HB,. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35(5 Suppl 2): S72-S78.
4. Bosch FX, Ribes J, Díaz M, Cléries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5-S16.
5. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
6. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP,. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-25.
7. Nakanuma Y, Mashiso H, Tadashi T,. Clinical and pathologic features of cholangiocarcinoma. In:, Okuda K, Tabor E, eds. Liver cancer. New York: Churchill Livingstone, 1997. 279-90.
8. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC,. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-13.
9. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C,. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-45.
10. El-Serag HB,. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1): S27-S34.
11. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-7.
12. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr,. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-6.
13. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT,. Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends. Int J Cancer 2007; 121: 1624-6.
14. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT,. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007; 99: 895-7.
15. Eckel RH, Grundy SM, Zimmet PZ,. The metabolic syndrome. Lancet 2005; 365: 1415-28.
16. Cowey S, Hardy RW,. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006; 169: 1505-22.
17. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-41.
18. El-Serag HB, Tran T, Everhart JE,. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
19. Nair S, Mason A, Eason J, Loss G, Perrillo RP,. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002; 36: 150-5.
20. Stocks T, Borena W, Strohmaier S, Bjorge T, Manjer J, Engeland A, Johansen D, Selmer R, Hallmans G, Rapp K, Concin H, Jonsson H, et al. Cohort profile: the Metabolic syndrome and Cancer project (Me-Can). Int J Epidemiol 2010; 39: 660-7.
21. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation, 1999.
22. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
23. Roth GA, Fihn SD, Mokdad AH, Aekplakorn W, Hasegawa T, Lim SS,. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. Bull World Health Organ 2011; 89: 92-101.
24. Pokorny AD, Miller BA, Kaplan HB,. The Brief MAST. A shortened version of the Michigan Alcoholism Screening Test. Am J Psychiatry 1972; 129: 342-5.
25. Kristenson H, Trell E,. Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. Br J Addict 1982; 77: 297-304.
26. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, Peto R,. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999; 150: 341-53.
27. Wood AM, White I, Thompson SG, Lewington S, Danesh J,. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol 2006; 35: 1570-8.
28. Fibrinogen Studies Collaboration,. Correcting for multivariate measurement error by regression calibration in meta-analyses of epidemiological studies. Stat Med 2009; 28: 1067-92.
29. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G,. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.
30. Fan AZ, Russell M, Naimi T, Li Y, Liao Y, Jiles R, Mokdad AH,. Patterns of alcohol consumption and the metabolic syndrome. J Clin Endocrinol Metab 2008; 93: 3833-8.
31. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ,. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
32. Møller H, Mellemgaard A, Lindvig K, Olsen JH,. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer A 1994; 30: 344-50.
33. Wolk A, Gridley G, Svensson M, Nyrén O, McLaughlin JK, Fraumeni JF, Adam HO,. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001; 12: 13-21.
34. Oh SW, Yoon YS, Shin SA,. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-54.
35. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM,. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S97-S103.
36. Grossman E, Messerli FH, Boyko V, Goldbourt U,. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112: 479-86.
37. P Meyer,. Increased intracellular calcium: from hypertension to cancer. J Hypertens Suppl 1987; 5: S3-S4.
38. El-Serag HB, Hampel H, Javadi F,. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
39. Angulo P, Keach JC, Batts KP, Lindor KD,. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
40. Wanless IR, Lentz JS,. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12: 1106-10.
41. Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, Wolk A, McLaughlin JK, Fraumeni JF Jr,. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996; 88: 1472-7.
42. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S, Borch-Johnsen K, Olsen JH,. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89: 1360-5.
43. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ,. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159: 1160-7.
44. Fujino Y, Mizoue T, Tokui N, Yoshimura T,. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Rev 2001; 17: 374-9.
45. La Vecchia C, Negri E, Decarli A, Franceschi S,. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer 1997; 73: 204-7.
46. Strasak AM, Pfeiffer RM, Brant LJ, Rapp K, Hilbe W, Oberaigner W, Lang S, Borena W, Concin H, Diem G, Ruttmann E, Glodny B, et al. VHM&PP Study Group. Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up study. Ann Oncol 2009; 20: 1113-20.
47. Eggens I, Ekström TJ, Aberg F,. Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas. J Exp Pathol (Oxford) 1990; 71: 219-32.
48. Jiang JT, Xu N, Zhang XY, Wu CP,. Lipids changes in liver cancer. J Zhejiang Univ Sci B 2007; 8: 398-409.
49. Michelini E, Lonardo A, Ballestri S, Costantini M, Caporali C, Bonati ME, Bertolotti M, Iori R, Loria P,. Is cholangiocarcinoma another complication of insulin resistance: a report of three cases. Metab Syndr Relat Disord 2007; 5: 194-202.
50. Siegel AB, Zhu AX,. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-61.